{
  "parties": [
    "DOVA PHARMACEUTICALS, INC",
    "VALEANT PHARMACEUTICALS NORTH AMERICA LLC"
  ],
  "effective_date": null,
  "governing_law": null,
  "payment_terms": null,
  "termination_clause": {
    "text": "TERMINATION 41\n\n12.1 Term. 41\n\n12.2 Early Termination for Cause. 41\n\nSource: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\n\n\n\n\n\n12.3 Other Early Termination. 42\n\n12.4 Effects of Termination. 42\n\n12.5 Tail Period. 42\n\nii\n\nCONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.\n\nSource: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018\n\n\n\n\n\nTABLE OF CONTENTS (continued)\n\n12.6 Survival. 43\n\nARTICLE 13 MISCELLANEOUS 43\n\n13.1 Force Majeure. 43\n\n13.2 Assignment. 43\n\n13.3 Severability. 44\n\n13.4 Notices. 44\n\n13.5 Governing Law. 45\n\n13.6 Dispute Resolution. 45\n\n13.7 Waiver of Jury Tria",
    "start": 3297,
    "end": 4108,
    "confidence": 0.72,
    "source": "regex"
  },
  "_doc_id": "DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_11414857_EX-10.2_Promotion Agreement.txt",
  "_char_count": 175580,
  "_provenance": {},
  "_issues": [
    {
      "type": "MISSING",
      "field": "payment_terms"
    },
    {
      "type": "MISSING",
      "field": "governing_law"
    }
  ]
}